TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3.Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2.Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. GLOBAL COMPOUNDED PHARMACY MARKET, BY PRODUCT
6.1. Overview
6.2. Topical Medications
6.3. Parenteral Medications
6.4. Oral Medications
6.5. Other Medications
7. GLOBAL COMPOUNDED PHARMACY MARKET, BY THERAPEUTIC AREA
7.1. Overview
7.2. Hormone Replacement
7.3. Pain Management
7.4. Dermal Disorders
7.5. Others
8. GLOBAL COMPOUNDED PHARMACY MARKET, BY COMPOUNDING TYPE
8.1. Overview
8.2. Pharmaceutical Ingredient Alteration
8.3. Currently Unavailable Pharmaceutical Manufacturing
8.4. Pharmaceutical Dosage Alteration
8.5. Others
9. GLOBAL COMPOUNDED PHARMACY MARKET, BY REGION
9.1. Overview
9.1. North America
9.1.1. US
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. France
9.2.3. UK
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia-Pacific
9.3.1. China
9.3.2. India
9.3.3. Japan
9.3.4. South Korea
9.3.5. Australia
9.3.6. Rest of Asia-Pacific
9.4. Rest of the World
9.4.1. Middle East
9.4.2. Africa
9.4.3. Latin America
10. COMPETITIVE LANDSCAPE
10.1. Overview
10.2. Competitive Analysis
10.3. Market Share Analysis
10.4. Major Growth Strategy in the Global Compounded Pharmacy Market,
10.5. Competitive Benchmarking
10.6. Leading Players in Terms of Number of Developments in the Global Compounded Pharmacy Market,
10.7. Key developments and Growth Strategies
10.7.1. New Product Launch/Service Deployment
10.7.2. Merger & Acquisitions
10.7.3. Joint Ventures
10.8. Major Players Financial Matrix
10.8.1. Sales & Operating Income, 2023
10.8.2. Major Players R&D Expenditure. 2023
11. COMPANY PROFILES
11.1. FAGRON
11.1.1. Company Overview
11.1.2. Financial Overview
11.1.3. Products Offered
11.1.4. Key Developments
11.1.5. SWOT Analysis
11.1.6. Key Strategies
11.2. Walgreen Co.
11.2.1. Company Overview
11.2.2. Financial Overview
11.2.3. Products Offered
11.2.4. Key Developments
11.2.5. SWOT Analysis
11.2.6. Key Strategies
11.3. JL Diekman and AQ Touchard (Fresh Therapeutics Compounding Pharmacy)
11.3.1. Company Overview
11.3.2. Financial Overview
11.3.3. Products Offered
11.3.4. Key Developments
11.3.5. SWOT Analysis
11.3.6. Key Strategies
11.4. Albertsons Companies
11.4.1. Company Overview
11.4.2. Financial Overview
11.4.3. Products Offered
11.4.4. Key Developments
11.4.5. SWOT Analysis
11.4.6. Key Strategies
11.5. Galenic Laboratories Limited (Roseway Labs)
11.5.1. Company Overview
11.5.2. Financial Overview
11.5.3. Products Offered
11.5.4. Key Developments
11.5.5. SWOT Analysis
11.5.6. Key Strategies
11.6. The London Specialist Pharmacy Ltd (Specialist Pharmacy)
11.6.1. Company Overview
11.6.2. Financial Overview
11.6.3. Products Offered
11.6.4. Key Developments
11.6.5. SWOT Analysis
11.6.6. Key Strategies
11.7. Apollo Clinical Pharmacy
11.7.1. Company Overview
11.7.2. Financial Overview
11.7.3. Products Offered
11.7.4. Key Developments
11.7.5. SWOT Analysis
11.7.6. Key Strategies
11.8. MEDS Pharmacy
11.8.1. Company Overview
11.8.2. Financial Overview
11.8.3. Products Offered
11.8.4. Key Developments
11.8.5. SWOT Analysis
11.8.6. Key Strategies
11.9. AURORA COMPOUNDING
11.9.1. Company Overview
11.9.2. Financial Overview
11.9.3. Products Offered
11.9.4. Key Developments
11.9.5. SWOT Analysis
11.9.6. Key Strategies
11.10. FORMUL8
11.10.1. Company Overview
11.10.2. Financial Overview
11.10.3. Products Offered
11.10.4. Key Developments
11.10.5. SWOT Analysis
11.10.6. Key Strategies
11.11. Fusion Apothecary
11.11.1. Company Overview
11.11.2. Financial Overview
11.11.3. Products Offered
11.11.4. Key Developments
11.11.5. SWOT Analysis
11.11.6. Key Strategies
12. APPENDIX
12.1. References
12.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL COMPOUNDED PHARMACY MARKET, SYNOPSIS, 2019-2032
TABLE 2 GLOBAL COMPOUNDED PHARMACY MARKET, ESTIMATES & FORECAST, 2019-2032 (USD BILLION)
TABLE 3 GLOBAL COMPOUNDED PHARMACY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 4 GLOBAL COMPOUNDED PHARMACY MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 5 GLOBAL COMPOUNDED PHARMACY MARKET, BY COMPOUNDING TYPE, 2019-2032 (USD BILLION)
TABLE 6 NORTH AMERICA: COMPOUNDED PHARMACY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 7 NORTH AMERICA: COMPOUNDED PHARMACY MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 8 NORTH AMERICA: COMPOUNDED PHARMACY MARKET, BY COMPOUNDING TYPE, 2019-2032 (USD BILLION)
TABLE 9 US: COMPOUNDED PHARMACY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 10 US: COMPOUNDED PHARMACY MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 11 US: COMPOUNDED PHARMACY MARKET, BY COMPOUNDING TYPE, 2019-2032 (USD BILLION)
TABLE 12 CANADA: COMPOUNDED PHARMACY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 13 CANADA: COMPOUNDED PHARMACY MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 14 CANADA: COMPOUNDED PHARMACY MARKET, BY COMPOUNDING TYPE, 2019-2032 (USD BILLION)
TABLE 1 EUROPE: COMPOUNDED PHARMACY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 2 EUROPE: COMPOUNDED PHARMACY MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 3 EUROPE: COMPOUNDED PHARMACY MARKET, BY COMPOUNDING TYPE, 2019-2032 (USD BILLION)
TABLE 4 GERMANY: COMPOUNDED PHARMACY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 5 GERMANY: COMPOUNDED PHARMACY MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 6 GERMANY: COMPOUNDED PHARMACY MARKET, BY COMPOUNDING TYPE, 2019-2032 (USD BILLION)
TABLE 7 FRANCE: COMPOUNDED PHARMACY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 8 FRANCE: COMPOUNDED PHARMACY MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 9 FRANCE: COMPOUNDED PHARMACY MARKET, BY COMPOUNDING TYPE, 2019-2032 (USD BILLION)
TABLE 10 ITALY: COMPOUNDED PHARMACY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 11 ITALY: COMPOUNDED PHARMACY MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 12 ITALY: COMPOUNDED PHARMACY MARKET, BY COMPOUNDING TYPE, 2019-2032 (USD BILLION)
TABLE 13 SPAIN: COMPOUNDED PHARMACY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 14 SPAIN: COMPOUNDED PHARMACY MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 15 SPAIN: COMPOUNDED PHARMACY MARKET, BY COMPOUNDING TYPE, 2019-2032 (USD BILLION)
TABLE 16 UK: COMPOUNDED PHARMACY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 17 UK: COMPOUNDED PHARMACY MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 18 UK: COMPOUNDED PHARMACY MARKET, BY COMPOUNDING TYPE, 2019-2032 (USD BILLION)
TABLE 19 REST OF EUROPE: COMPOUNDED PHARMACY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 20 REST OF EUROPE: COMPOUNDED PHARMACY MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 21 REST OF EUROPE: COMPOUNDED PHARMACY MARKET, BY COMPOUNDING TYPE, 2019-2032 (USD BILLION)
TABLE 22 ASIA-PACIFIC: COMPOUNDED PHARMACY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 23 ASIA-PACIFIC: COMPOUNDED PHARMACY MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 24 ASIA-PACIFIC: COMPOUNDED PHARMACY MARKET, BY COMPOUNDING TYPE, 2019-2032 (USD BILLION)
TABLE 25 JAPAN: COMPOUNDED PHARMACY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 26 JAPAN: COMPOUNDED PHARMACY MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 27 JAPAN: COMPOUNDED PHARMACY MARKET, BY COMPOUNDING TYPE, 2019-2032 (USD BILLION)
TABLE 28 CHINA: COMPOUNDED PHARMACY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 29 CHINA: COMPOUNDED PHARMACY MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 30 CHINA: COMPOUNDED PHARMACY MARKET, BY COMPOUNDING TYPE, 2019-2032 (USD BILLION)
TABLE 31 INDIA: COMPOUNDED PHARMACY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 32 INDIA: COMPOUNDED PHARMACY MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 33 INDIA: COMPOUNDED PHARMACY MARKET, BY COMPOUNDING TYPE, 2019-2032 (USD BILLION)
TABLE 34 AUSTRALIA: COMPOUNDED PHARMACY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 35 AUSTRALIA: COMPOUNDED PHARMACY MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 36 AUSTRALIA: COMPOUNDED PHARMACY MARKET, BY COMPOUNDING TYPE, 2019-2032 (USD BILLION)
TABLE 37 SOUTH KOREA: COMPOUNDED PHARMACY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 38 SOUTH KOREA: COMPOUNDED PHARMACY MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 39 SOUTH KOREA: COMPOUNDED PHARMACY MARKET, BY COMPOUNDING TYPE, 2019-2032 (USD BILLION)
TABLE 40 REST OF ASIA-PACIFIC: COMPOUNDED PHARMACY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 41 REST OF ASIA-PACIFIC: COMPOUNDED PHARMACY MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 42 REST OF ASIA-PACIFIC: COMPOUNDED PHARMACY MARKET, BY COMPOUNDING TYPE, 2019-2032 (USD BILLION)
TABLE 43 REST OF THE WORLD: COMPOUNDED PHARMACY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 44 REST OF THE WORLD: COMPOUNDED PHARMACY MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 45 REST OF THE WORLD: COMPOUNDED PHARMACY MARKET, BY COMPOUNDING TYPE, 2019-2032 (USD BILLION)
TABLE 46 MIDDLE EAST: COMPOUNDED PHARMACY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 47 MIDDLE EAST: COMPOUNDED PHARMACY MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 48 MIDDLE EAST: COMPOUNDED PHARMACY MARKET, BY COMPOUNDING TYPE, 2019-2032 (USD BILLION)
TABLE 49 AFRICA: COMPOUNDED PHARMACY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 50 AFRICA: COMPOUNDED PHARMACY MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 51 AFRICA: COMPOUNDED PHARMACY MARKET, BY COMPOUNDING TYPE, 2019-2032 (USD BILLION)
TABLE 52 LATIN AMERICA: COMPOUNDED PHARMACY MARKET, BY PRODUCT, 2019-2032 (USD BILLION)
TABLE 53 LATIN AMERICA: COMPOUNDED PHARMACY MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD BILLION)
TABLE 54 LATIN AMERICA: COMPOUNDED PHARMACY MARKET, BY COMPOUNDING TYPE, 2019-2032 (USD BILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL COMPOUNDED PHARMACY MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL COMPOUNDED PHARMACY MARKET
FIGURE 4 GLOBAL COMPOUNDED PHARMACY MARKET, SHARE (%), BY PRODUCT, 2023
FIGURE 5 GLOBAL COMPOUNDED PHARMACY MARKET, SHARE (%), BY THERAPEUTIC AREA, 2023
FIGURE 6 GLOBAL COMPOUNDED PHARMACY MARKET, SHARE (%), BY COMPOUNDING TYPE, 2023
FIGURE 7 GLOBAL COMPOUNDED PHARMACY MARKET, SHARE (%), BY REGION, 2023
FIGURE 8 NORTH AMERICA: COMPOUNDED PHARMACY MARKET, SHARE (%), BY REGION, 2023
FIGURE 9 EUROPE: COMPOUNDED PHARMACY MARKET, SHARE (%), BY REGION, 2023
FIGURE 10 ASIA-PACIFIC: COMPOUNDED PHARMACY MARKET, SHARE (%), BY REGION, 2023
FIGURE 11 REST OF THE WORLD: COMPOUNDED PHARMACY MARKET, SHARE (%), BY REGION, 2023
FIGURE 12 GLOBAL COMPOUNDED PHARMACY MARKET: COMPANY SHARE ANALYSIS, 2023 (%)
FIGURE 13 FAGRON: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 14 FAGRON: SWOT ANALYSIS
FIGURE 15 WALGREEN CO.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 16 WALGREEN CO.: SWOT ANALYSIS
FIGURE 17 JL DIEKMAN AND AQ TOUCHARD (FRESH THERAPEUTICS COMPOUNDING PHARMACY): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 18 JL DIEKMAN AND AQ TOUCHARD (FRESH THERAPEUTICS COMPOUNDING PHARMACY): SWOT ANALYSIS
FIGURE 19 ALBERTSONS COMPANIES: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 20 ALBERTSONS COMPANIES: SWOT ANALYSIS
FIGURE 21 GALENIC LABORATORIES LIMITED (ROSEWAY LABS): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 22 GALENIC LABORATORIES LIMITED (ROSEWAY LABS): SWOT ANALYSIS
FIGURE 23 THE LONDON SPECIALIST PHARMACY LTD (SPECIALIST PHARMACY): FINANCIAL OVERVIEW SNAPSHOT
FIGURE 24 THE LONDON SPECIALIST PHARMACY LTD (SPECIALIST PHARMACY): SWOT ANALYSIS
FIGURE 25 APOLLO CLINICAL PHARMACY: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 26 APOLLO CLINICAL PHARMACY: SWOT ANALYSIS
FIGURE 27 MEDS PHARMACY: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 28 MEDS PHARMACY: SWOT ANALYSIS
FIGURE 29 AURORA COMPOUNDING: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 30 AURORA COMPOUNDING: SWOT ANALYSIS
FIGURE 31 FORMUL8: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 32 FORMUL8: SWOT ANALYSIS
FIGURE 33 FUSION APOTHECARY: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 34 FUSION APOTHECARY: SWOT ANALYSIS
